Stay updated on Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi

Sign up to get notified when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Publication entry updated to reflect a full 2026 Clin Lung Cancer article by the SAVANNAH study authors with a DOI. The previous 'Online ahead of print' citation was removed.
    Difference
    0.1%
    Check dated 2026-03-06T18:02:19.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    The updates add posted results and expand efficacy/safety endpoints (ORR, DoR, PFS, OS) with detailed time frames; they also remove multiple protocol-based biospecimen collection and exploratory analyses.
    Difference
    4%
    Check dated 2026-02-13T11:58:01.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Added Revision: v3.4.1 and removed Revision: v3.4.0.
    Difference
    0.0%
    Check dated 2026-02-05T15:08:14.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    Footer now displays Revision: v3.3.4 and the previous Revision: v3.3.3 has been removed.
    Difference
    0.0%
    Check dated 2026-01-15T03:08:01.000Z thumbnail image
  7. Check
    83 days ago
    Change Detected
    Summary
    Added and updated the Locations sections to include California, District of Columbia, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Washington, and Alberta/Ontario; removed the prior state-location entries and the HHS Vulnerability Disclosure link.
    Difference
    0.6%
    Check dated 2025-12-24T14:36:17.000Z thumbnail image
  8. Check
    105 days ago
    Change Detected
    Summary
    Publications section added: Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial. This update does not alter the study design, eligibility criteria, endpoints, or enrollment.
    Difference
    0.0%
    Check dated 2025-12-02T17:57:23.000Z thumbnail image

Stay in the know with updates to Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.